Liquidia stock price target cut to $58 by H.C. Wainwright on patent uncertainty
H.C. Wainwright cut Liquidia Technologies' (LQDA) price target to $58 from $130 due to patent litigation with United Therapeutics, removing the PH-ILD indication from its financial model. The firm now focuses on the PAH indication and pipeline, projecting $1.1B in peak sales for Yutrepia by 2030. LQDA's stock has dropped 59% to $27.99, below its fair value of $34.75. Q2 2026 earnings showed mixed results, with EPS missing estimates but revenue exceeding projections.
How this was made
The 30-second read
Why it matters
The combination of earnings miss, patent uncertainty, and multiple analyst downgrades creates a bearish catalyst for the stock.
Market read
Analyst actions and litigation risk dominate the short-term outlook, suggesting downside pressure.
What to watch
Potential upside from the PAH indication and the L606 pipeline could mitigate litigation risk.
Background
Liquidia Technologies reported Q2 2026 earnings with EPS slightly missing expectations but revenue beating forecasts. Patent litigation with United Therapeutics prompted analyst target cuts and downgrades.
Ticker impact
H.C. Wainwright cut Liquidia's price target to $58 and downgraded the stock amid patent litigation and a weak Q2 earnings beat.
likely pressure as the market prices in the lower target and litigation uncertainty.
Multiple analysts simultaneously reduced ratings and targets, and the stock has already fallen 59% this week, indicating strong bearish sentiment.
Market effects
Biotech sector may see broader scrutiny of patent risks, potentially affecting peers with similar pipelines.
US biotech investors may reduce exposure to companies facing litigation.
Limited to investors tracking US-listed biotech stocks.
Counterpoint
The price cut may be overdone if the PAH pipeline shows strong upside potential.
Key entities
- companyLiquidia Technologies
US-listed biotech firm (NASDAQ:LQDA) developing inhaled therapies.
- analyst_firmH.C. Wainwright
Equity research firm that lowered the price target to $58.
